DermR Health, a biotech company focused on transforming skin cancer detection and diagnosis, has closed a $6.5M seed funding round. The capital will advance its work on a novel microsampling device and genetic testing platform designed to make diagnostics earlier, more accessible, and less invasive.
The company's ambitious goal is to replace 1 billion skin biopsies, addressing the inefficiency where over 60% of current procedures are ultimately found to be benign. This approach aims to improve global health equity by providing better testing solutions.
